[go: up one dir, main page]

MXPA02011511A - USO DE (+)-alfa û(2,3-dimetoxifenil)etil-1-[2-(4-fluorofenil)etil] -4-piperidin metanol o sus fármacos en el tratamiento de síntomas demencia y psicosis inducida por dofamina. - Google Patents

USO DE (+)-alfa û(2,3-dimetoxifenil)etil-1-[2-(4-fluorofenil)etil] -4-piperidin metanol o sus fármacos en el tratamiento de síntomas demencia y psicosis inducida por dofamina.

Info

Publication number
MXPA02011511A
MXPA02011511A MXPA02011511A MXPA02011511A MXPA02011511A MX PA02011511 A MXPA02011511 A MX PA02011511A MX PA02011511 A MXPA02011511 A MX PA02011511A MX PA02011511 A MXPA02011511 A MX PA02011511A MX PA02011511 A MXPA02011511 A MX PA02011511A
Authority
MX
Mexico
Prior art keywords
emethanol
agr
dimethoxyphenyl
piperidin
dementia
Prior art date
Application number
MXPA02011511A
Other languages
English (en)
Inventor
Janice Hitchcock
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MXPA02011511A publication Critical patent/MXPA02011511A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invencion se dirige al uso de (+)-(- (2, 3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinmetanol o sus profarmacos (formula (II)) en el tratamiento de pacientes para los sintomas de demencia y psicosis inducida por dopamina.
MXPA02011511A 2000-05-25 2001-05-23 USO DE (+)-alfa û(2,3-dimetoxifenil)etil-1-[2-(4-fluorofenil)etil] -4-piperidin metanol o sus fármacos en el tratamiento de síntomas demencia y psicosis inducida por dofamina. MXPA02011511A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20694300P 2000-05-25 2000-05-25
PCT/US2001/016653 WO2001089498A2 (en) 2000-05-25 2001-05-23 USE OF (+)-α -(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS

Publications (1)

Publication Number Publication Date
MXPA02011511A true MXPA02011511A (es) 2003-04-25

Family

ID=22768607

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011511A MXPA02011511A (es) 2000-05-25 2001-05-23 USO DE (+)-alfa û(2,3-dimetoxifenil)etil-1-[2-(4-fluorofenil)etil] -4-piperidin metanol o sus fármacos en el tratamiento de síntomas demencia y psicosis inducida por dofamina.

Country Status (20)

Country Link
US (3) US20020099076A1 (es)
EP (1) EP1289527B1 (es)
JP (1) JP2003535058A (es)
KR (1) KR100784655B1 (es)
CN (1) CN1436078A (es)
AR (1) AR029666A1 (es)
AT (1) ATE390134T1 (es)
AU (2) AU2001264842B2 (es)
BR (1) BR0111102A (es)
CA (1) CA2410554C (es)
DE (1) DE60133385T2 (es)
DK (1) DK1289527T3 (es)
ES (1) ES2300333T3 (es)
IL (1) IL152908A0 (es)
MX (1) MXPA02011511A (es)
NO (1) NO20025630L (es)
NZ (1) NZ522659A (es)
PT (1) PT1289527E (es)
TW (1) TWI299001B (es)
WO (1) WO2001089498A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE353693T1 (de) 2002-07-19 2007-03-15 Biovitrum Ab Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
ES2643615T3 (es) * 2004-09-30 2017-11-23 F. Hoffmann-La Roche Ag Composiciones y métodos para el tratamiento de trastornos cognitivos
DE102006040278A1 (de) * 2006-08-21 2008-03-20 Technische Universität Dresden Arzneimittel zur Behandlung des Charles-Bonnet-Syndroms
JP6850282B2 (ja) 2015-07-20 2021-03-31 アカディア ファーマシューティカルズ インコーポレーテッド Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミドならびにその酒石酸塩および多形形態ｃを調製する方法
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3436010B1 (en) * 2016-03-29 2021-03-10 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021428A (en) * 1985-07-02 1991-06-04 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds for the prophylactic treatment of migraine
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4912117A (en) * 1985-07-02 1990-03-27 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds
US4783471A (en) * 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
US4877798A (en) * 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
EP0325063B1 (en) * 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
US5106855A (en) * 1989-12-20 1992-04-21 Merrell Dow Pharmaceuticals Inc. Method for the treatment of glaucoma
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
JP2869512B2 (ja) * 1990-06-01 1999-03-10 メレルダウファーマスーティカルズ インコーポレイテッド （＋）―α―（２，３―ジメトキシフェニル）―１―［２―（４―フルオロフェニル）エチル］―４―ピペリジンメタノール
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
FR2738819B1 (fr) * 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
WO1999020315A1 (en) * 1997-10-23 1999-04-29 The Research Foundation Of State University Of New York Methods of screening potential atypical antipsychotic drugs
HK1040907B (zh) * 1998-08-28 2004-04-02 阿温蒂斯药物公司 R(+)-α-(2，3-二甲氧基苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇用於治疗睡眠障碍
EA003667B1 (ru) * 1998-10-14 2003-08-28 Авентис Фармасьютикалз Инк. Сложные эфиры (+)-альфа-(2,3-диметоксифенил)-1-[2-(4-фторфенил)этил]-4-пиперидинметанола и их использование в качестве пролекарств антагониста mdl 110907 5htрецепторов
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same

Also Published As

Publication number Publication date
TWI299001B (en) 2008-07-21
IL152908A0 (en) 2003-06-24
NO20025630L (no) 2003-01-24
EP1289527A2 (en) 2003-03-12
PL359176A1 (en) 2004-08-23
WO2001089498A3 (en) 2002-05-10
NZ522659A (en) 2004-06-25
PT1289527E (pt) 2008-05-13
US20040204457A1 (en) 2004-10-14
WO2001089498A2 (en) 2001-11-29
BR0111102A (pt) 2003-03-11
DE60133385T2 (de) 2009-04-23
EP1289527B1 (en) 2008-03-26
DE60133385D1 (de) 2008-05-08
US7132433B2 (en) 2006-11-07
AU6484201A (en) 2001-12-03
ES2300333T3 (es) 2008-06-16
NO20025630D0 (no) 2002-11-22
KR100784655B1 (ko) 2007-12-12
ATE390134T1 (de) 2008-04-15
CA2410554A1 (en) 2001-11-29
JP2003535058A (ja) 2003-11-25
KR20030034078A (ko) 2003-05-01
US20020099076A1 (en) 2002-07-25
CA2410554C (en) 2009-02-03
US20030036553A1 (en) 2003-02-20
DK1289527T3 (da) 2008-07-14
AU2001264842B2 (en) 2005-01-27
CN1436078A (zh) 2003-08-13
AR029666A1 (es) 2003-07-10

Similar Documents

Publication Publication Date Title
GB0005251D0 (en) Therapeutic compounds
AU2001271686A1 (en) Compounds to treat alzheimer's disease
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
WO2002002520A8 (en) Compounds to treat alzheimer's disease
NO953187D0 (no) Imidazopyridiner og deres anvendelse ved behandling av mave-tarm-sykdommer
GB0223038D0 (en) Therapeutic compounds
AU2001252958A1 (en) Compounds and methods to treat alzheimer's disease
GB0025173D0 (en) Therapeutic agents
WO2002002512A3 (en) Compounds to treat alzheimer's disease
GB0225475D0 (en) Therapeutic agents
GB0108591D0 (en) Therapeutic agents
GB0225474D0 (en) Therapeutic agents
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
IL171977A0 (en) Cyclic sulfonamides for inhibition of gamma-secretase
NZ514663A (en) Indigoid bisindole derivatives for treating solid cancers
AU1074702A (en) Sulfamides as gamma-secretase inhibitors
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
MXPA02011511A (es) USO DE (+)-alfa û(2,3-dimetoxifenil)etil-1-[2-(4-fluorofenil)etil] -4-piperidin metanol o sus fármacos en el tratamiento de síntomas demencia y psicosis inducida por dofamina.
NO20034301L (no) Cyano-substituerte dihydropyrimidin forbindelser
IL150125A0 (en) Novel compounds
MY133785A (en) Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
MXPA02012163A (es) Composiciones farmaceuticas que comprenden derivados de acriloil-distamicina e inhibidores de topoisomerasa 1 y 11.
MXPA02012209A (es) Terapia combinada contra tumores que comprende derivados de bistamicina acriloilo substituida y agentes de alquilacion.
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina

Legal Events

Date Code Title Description
FG Grant or registration